Key facts
- Notable investors include Moondust Ventures, Tensor Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aireen
- ·The full record, as it builds
Funding rounds
No funding rounds for Aireen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aireen
Developer of a medical technology designed to offer a non-invasive, painless screening of chronic diseases for individuals suffering from eye retina. The company's technology uses artificial intelligence to detect diabetes from images of the eye retina, offering results in about a minute, integrates into clinical workflows with cloud-based options and secure handling of data, enabling medical facilities and health systems to expand access to early disease detection while reducing workload and costs in preventive care.
- Sector
- Healthcare
- HQ
- Prague, Czech Republic
- Founded
- 2018
- Employees
- 17
- Website
- aireen.com/
- Ownership
- Privately Held (backing)
Aireen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aireen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aireen in its N-PORT filings yet. We sweep new filings monthly.